KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Uncomplicated Plasmodium Falciparum Malaria
Conditions
Acute Uncomplicated Plasmodium Falciparum Malaria
Trial Timeline
Aug 2, 2017 → Jun 28, 2021
NCT ID
NCT03167242About KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation
KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation is a phase 2 stage product being developed by Novartis for Acute Uncomplicated Plasmodium Falciparum Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT03167242. Target conditions include Acute Uncomplicated Plasmodium Falciparum Malaria.
What happened to similar drugs?
20 of 20 similar drugs in Acute Uncomplicated Plasmodium Falciparum Malaria were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03167242 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Uncomplicated Plasmodium Falciparum Malaria